Can a targeted drug boost the power of stem cell transplants for tough lymphoma?

This phase 2 trial is testing whether adding the targeted drug pirtobrutinib to a standard chemotherapy conditioning regimen (BEAM) before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study will enroll about 28 adults aged 18-70 who have achieved a partial or complete response after second-line or later therapy. The main goal is to see how long participants live without their disease progressing after the transplant, with secondary goals including overall survival, complete remission rates, and how quickly blood cells recover.